NEC‐related surgery during study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes NEC‐related surgery during study period compared with control (very low certainty).
1 finding from 1 review
NEC‐related deaths during study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes NEC‐related deaths during study period compared with control (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Muscle pain at rest · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
It is very uncertain whether summary of findings: whole‐body cryotherapy (WBC) changes muscle soreness: pain at rest (VAS) compared with control (no WBC or passive rest) (very low certainty).
4 findings from 1 review
no estimate extracted
2 studies · 20 participants
Very low
no estimate extracted
3 studies · 38 participants
Very low
no estimate extracted
3 studies · 38 participants
Very low
Show 1 more finding
Tiredness · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
General well‐being · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Adverse events · physically‐active adults partaking in exercise designed to produce delayed onset muscle soreness (most trial participants were male)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain VAS sum (decrease) on active standardized movement (mm) · patients with acute lower and upper back pain
1 finding from 1 review
ED visits · Nursing home residents (mean age 78.3 to 86.0 years; more than 66% women; 62.1% to 87.3% with dental prostheses)
Summary of findings: Any alternative model of care showed no clear difference in emergency department (ED) visits: proportion of residents with at… compared with usual care (low certainty).
1 finding from 1 review